Cargando…
New ways of assessing ovarian cancer response: metabolic imaging and beyond
In patients with advanced ovarian cancer, it can be challenging to evaluate response to neoadjuvant chemotherapy on computed tomography (CT) due to disseminated small volume disease and serosal disease. In addition, measuring the change in size of tumour burden takes time in order to allow tumour sh...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
e-Med
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460555/ https://www.ncbi.nlm.nih.gov/pubmed/23022953 http://dx.doi.org/10.1102/1470-7330.2012.9004 |
_version_ | 1782244952118394880 |
---|---|
author | Rockall, Andrea Munari, Alice Avril, Norbert |
author_facet | Rockall, Andrea Munari, Alice Avril, Norbert |
author_sort | Rockall, Andrea |
collection | PubMed |
description | In patients with advanced ovarian cancer, it can be challenging to evaluate response to neoadjuvant chemotherapy on computed tomography (CT) due to disseminated small volume disease and serosal disease. In addition, measuring the change in size of tumour burden takes time in order to allow tumour shrinkage. Despite these challenges, serum CA-125 levels and CT are the standard tools for the assessment of treatment response in ovarian cancer. New functional imaging techniques may allow the identification of response earlier and with higher accuracy. In this review article, we describe the current literature on functional imaging techniques in ovarian cancer response assessment, focusing on fluorodeoxyglucose-positron emission tomography. |
format | Online Article Text |
id | pubmed-3460555 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | e-Med |
record_format | MEDLINE/PubMed |
spelling | pubmed-34605552014-06-13 New ways of assessing ovarian cancer response: metabolic imaging and beyond Rockall, Andrea Munari, Alice Avril, Norbert Cancer Imaging Advanced Ovarian Cancer In patients with advanced ovarian cancer, it can be challenging to evaluate response to neoadjuvant chemotherapy on computed tomography (CT) due to disseminated small volume disease and serosal disease. In addition, measuring the change in size of tumour burden takes time in order to allow tumour shrinkage. Despite these challenges, serum CA-125 levels and CT are the standard tools for the assessment of treatment response in ovarian cancer. New functional imaging techniques may allow the identification of response earlier and with higher accuracy. In this review article, we describe the current literature on functional imaging techniques in ovarian cancer response assessment, focusing on fluorodeoxyglucose-positron emission tomography. e-Med 2012-09-28 /pmc/articles/PMC3460555/ /pubmed/23022953 http://dx.doi.org/10.1102/1470-7330.2012.9004 Text en © 2012 International Cancer Imaging Society |
spellingShingle | Advanced Ovarian Cancer Rockall, Andrea Munari, Alice Avril, Norbert New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title | New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title_full | New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title_fullStr | New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title_full_unstemmed | New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title_short | New ways of assessing ovarian cancer response: metabolic imaging and beyond |
title_sort | new ways of assessing ovarian cancer response: metabolic imaging and beyond |
topic | Advanced Ovarian Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460555/ https://www.ncbi.nlm.nih.gov/pubmed/23022953 http://dx.doi.org/10.1102/1470-7330.2012.9004 |
work_keys_str_mv | AT rockallandrea newwaysofassessingovariancancerresponsemetabolicimagingandbeyond AT munarialice newwaysofassessingovariancancerresponsemetabolicimagingandbeyond AT avrilnorbert newwaysofassessingovariancancerresponsemetabolicimagingandbeyond |